Vizgen Company Profile

Background

Founded in 2019 and headquartered in Cambridge, Massachusetts, Vizgen is a pioneering life sciences company specializing in spatial genomics. The company's mission is to empower researchers with superior spatial biology tools, driving groundbreaking discoveries that enhance human health and well-being. Vizgen envisions a future where every disease is precisely mapped, charting clear paths to cures and transforming the landscape of medical research and therapy. By developing and commercializing the MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization) technology, Vizgen has enabled precise molecular and cellular mapping within biological systems, preserving vital spatial relationships critical for understanding tissue organization in health and disease.

Key Strategic Focus

Vizgen's strategic focus centers on advancing spatial genomics through the development and commercialization of its MERSCOPE™ platform. This platform facilitates massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. The company targets a wide range of applications, including oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and drug discovery and development. By providing researchers with tools to explore cellular functions and interactions with unprecedented clarity, Vizgen aims to set the standard in the spatial genomics field.

Financials and Funding

Vizgen has successfully secured multiple funding rounds to support its growth and innovation:

• Series A (January 2020): Raised $14 million, led by ARCH Venture Partners and Northpond Ventures.

• Series B (April 2021): Secured $37 million, co-led by Novalis LifeSciences LLC and Northpond Ventures, with participation from Tao Capital Partners, Pura Vida Investments, LLC, and a large U.S. endowment fund.

• Series C (April 2022): Raised $85.2 million, with investors including ARCH Venture Partners, Blue Water Life Science Advisors, David Walt, Northpond Ventures, Novalis LifeSciences, Sofina, and Tao Capital Partners.

• Series D (October 2024): Completed concurrent with the merger with Ultivue, with participation from ARCH Venture Partners, Northpond Ventures, and Tao Capital Partners.

These funds have been utilized to accelerate company growth, expand infrastructure, and support the commercialization of the MERSCOPE™ platform.

Technological Platform and Innovation

Vizgen's proprietary MERFISH technology is a cornerstone of its innovation, enabling massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. This technology allows researchers to map thousands of genes at single-cell resolution, providing transformative insights into tissue-scale basic research and translational medicine. The MERSCOPE™ platform integrates MERFISH technology into a user-friendly system, facilitating high-throughput studies with ease. Additionally, Vizgen offers predesigned gene panels and lab services to streamline research workflows.

Leadership Team

Vizgen's leadership team comprises experienced professionals dedicated to advancing spatial genomics:

• Rob Carson: President and CEO of the merged Vizgen entity. Previously served as CEO and President at Ultivue, with executive roles at Medtronic, Waters, and Harbinger Health.

• Terry Lo: Former CEO of Vizgen prior to the merger, now serving on the company's board. Led Vizgen through significant growth, global expansion, and strategic transformation.

• Dr. Mickael Ploquin: Regional Director for EMEA. Previously served as Sales and Market Development Manager, EMEA, at DNA Script, and oversaw 10x Genomics' growth in France.

Leadership Changes

In October 2024, Vizgen merged with Ultivue, leading to significant leadership changes. Rob Carson, former CEO of Ultivue, assumed the role of President and CEO of the combined entity, while Terry Lo transitioned to a board member position.

Competitor Profile

Market Insights and Dynamics

The spatial genomics market is experiencing rapid growth, driven by advancements in single-cell analysis technologies and increasing applications in research and clinical settings. The integration of spatial transcriptomics and proteomics is enhancing our understanding of complex biological systems, leading to new insights in disease mechanisms and therapeutic development.

Competitor Analysis

Key competitors in the spatial genomics field include:

• 10x Genomics: Offers the Xenium In Situ platform for single-cell spatial imaging. Engaged in patent litigation with Vizgen, which was settled in early 2025.

• Bruker: Provides spatial biology platforms such as CosMx and GeoMx. Settled patent disputes with 10x Genomics in mid-2025.

• NanoString Technologies: Developed spatial transcriptomics platforms but faced financial challenges, leading to acquisition by Bruker in 2024.

Strategic Collaborations and Partnerships

Vizgen has established significant collaborations to strengthen its market position and innovation capacity:

• Merger with Ultivue (October 2024): Combined expertise in spatial transcriptomics and proteomics to advance multi-omic research, creating a unified platform for studying genes and proteins in their spatial context.

• International Expansion (October 2022): Expanded availability of the MERSCOPE™ platform into Asia-Pacific (APAC), Europe, the Middle East, and Africa (EMEA) through agreements with distributors in China, Japan, Australia, South Korea, Switzerland, and Israel.

Operational Insights

Vizgen's strategic merger with Ultivue has positioned the company as a leader in spatial biology, offering integrated solutions that combine spatial transcriptomics and proteomics. This consolidation enhances Vizgen's competitive advantage by providing comprehensive multi-omic insights, catering to the growing demand for integrated spatial analysis in research and clinical applications. The company's international expansion further solidifies its market presence, enabling access to a broader customer base and fostering global collaborations.

Strategic Opportunities and Future Directions

Vizgen is poised to capitalize on several strategic opportunities:

• Clinical Applications: By enhancing the sensitivity and reproducibility of its technologies, Vizgen aims to extend its reach into clinical lab settings, facilitating the adoption of spatial genomics in diagnostics and personalized medicine.

• Product Development: Continued innovation in the MERSCOPE™ platform and expansion of gene panels and lab services will address the evolving needs of researchers and clinicians, driving further adoption of Vizgen's solutions.

• Global Expansion: Building on its existing international presence, Vizgen plans to deepen market penetration in APAC and EMEA regions, leveraging local partnerships and distribution networks to support growth.

Contact Information

• Website: www.vizgen.com

• Social Media:

• Twitter: @VizgenInc

• LinkedIn: Vizgen

• Facebook: Vizgen

Vizgen's commitment to innovation and strategic growth positions it as a key player in the spatial genomics landscape, driving advancements that enhance our understanding of human health and disease.